Tumor radiosensitizers--current status of development of various approaches: report of an International Atomic Energy Agency meeting.
Authors
Horsman, Michael RBohm, Lothar
Margison, Geoffrey P
Milas, Luka
Rosier, Jean-Francois
Safrany, Geza
Selzer, Edgar
Verheij, Marcel
Hendry, Jolyon H
Affiliation
Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark.Issue Date
2006-02-01
Metadata
Show full item recordAbstract
PURPOSE: The International Atomic Energy Agency (IAEA) held a Technical Meeting of Consultants to (1) discuss a selection of relatively new agents, not those well-established in clinical practice, that operated through a variety of mechanisms to sensitize tumors to radiation and (2) to compare and contrast their tumor efficacy, normal tissue toxicity, and status of development regarding clinical application. The aim was to advise the IAEA as to which developing agent or class of agents would be worth promoting further, by supporting additional laboratory research or clinical trials, with the eventual goal of improving cancer control rates using radiotherapy, in developing countries in particular. RESULTS: The agents under discussion included a wide, but not complete, range of different types of drugs, and antibodies that interfered with molecules in cell signaling pathways. These were contrasted with new molecular antisense and gene therapy strategies. All the drugs discussed have previously been shown to act as tumor cell radiosensitizers or to kill hypoxic cells present in tumors. CONCLUSION: Specific recommendations were made for more preclinical studies with certain of the agents and for clinical trials that would be suitable for industrialized countries, as well as trials that were considered more appropriate for developing countries.Citation
Tumor radiosensitizers--current status of development of various approaches: report of an International Atomic Energy Agency meeting. 2006, 64 (2):551-61 Int. J. Radiat. Oncol. Biol. Phys.Journal
International Journal of Radiation Oncology, Biology, PhysicsDOI
10.1016/j.ijrobp.2005.09.032PubMed ID
16414371Type
ArticleLanguage
enISSN
0360-3016ae974a485f413a2113503eed53cd6c53
10.1016/j.ijrobp.2005.09.032
Scopus Count
Collections
Related articles
- Hypoxic radiosensitizers and hypoxic cytotoxins in radiation oncology.
- Authors: Weinmann M, Welz S, Bamberg M
- Issue date: 2003 Sep
- [Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials].
- Authors: Azria D, Larbouret C, Robert B, Culine S, Ychou M, Verrelle P, Dubois JB, Pèlegrin A
- Issue date: 2003 Nov
- Sulfoglycolipids as candidate antiangiogenic radiosensitizers.
- Authors: Miura M, Sakimoto I, Ohta K, Sugawara F, Sakaguchi K
- Issue date: 2007 Jan
- Radiation sensitization with redox modulators: a promising approach.
- Authors: Rosenberg A, Knox S
- Issue date: 2006 Feb 1
- Mechanisms of disease: Radiosensitization by epidermal growth factor receptor inhibitors.
- Authors: Sartor CI
- Issue date: 2004 Dec